Aurobindo gets nod for HIV drug

Aurobindo Pharma Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524804 | NSE: AUROPHARMA

24 Feb 2009 Evaluate

Aurobindo Pharma Ltd has received tentative approval for Tenofovir Disoproxil Fumarate tablets in 300 mg dosage from the US Food & Drug Administration (USFDA). It is the generic equivalent of Gilead Sciences Inc. Viread tablets 300 mg and falls under the Anti-Retroviral (ARV) segment.

The drug is indicated in combination with other ARVs for the treatment of HIV-I infection in adults. The Abbreviated New Drug Application (ANDA) was reviewed under the expedited provisions of the President’s Emergency Plan for AIDS relief (PEPFAR) in the US.

Aurobindo has obtained licence from Gilead for marketing Tenofovir products in 95 developing and least developed countries. So far the Hyderabad-based pharma major has a total of 921 ANDA approvals (66 final and 25 tentative) from the USFDA. crack crack

Peers

Company Name	CMP
Sun Pharma. Inds.	1861.75
Dr. Reddys Labs.	1172.60
Cipla	1379.35
Lupin	2079.45
Zydus Lifesciences	1137.05
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.